Mutations in OCRL are found in individuals with the X-linked oculocerebral-renal syndrome of Lowe (Lowe syndrome) 1 and Dent disease 2 . Lowe syndrome is characterized by renal tubular dysfunction, behavioral difficulties, developmental delay and congenital cataracts 1, [3] [4] [5] [6] . Individuals with Dent disease have kidney defects similar to those in Lowe syndrome but with no or mild associated defects. The two disorders probably represent a phenotypic continuum 7, 8 .
a r t i c l e s
Mutations in OCRL are found in individuals with the X-linked oculocerebral-renal syndrome of Lowe (Lowe syndrome) 1 and Dent disease 2 . Lowe syndrome is characterized by renal tubular dysfunction, behavioral difficulties, developmental delay and congenital cataracts 1, [3] [4] [5] [6] . Individuals with Dent disease have kidney defects similar to those in Lowe syndrome but with no or mild associated defects. The two disorders probably represent a phenotypic continuum 7, 8 .
OCRL belongs to the inositol 5-phosphatase family, a group of enzymes that dephosphorylate the 5′ position of the inositol ring. In these enzymes, the catalytic core is typically delimited on either side by regions that specify the cellular localization and distinct function of each enzyme. In OCRL the central 5-phosphatase domain, whose preferred substrates are phosphatidylinositol-4,5-biphosphate (PtdIns(4,5)P 2 ) and phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P 3 ), is flanked by an N-terminal pleckstrin homology (PH) domain and at the C terminus by an ASPM-SPD2-hydin (ASH) domain followed by a catalytically inactive Rho GTPase activating (RhoGAP) domain (Fig. 1a) . The ASH and RhoGAP domains are joined by a hydrophobic interface to form a single unit owing to the stabilizing effect of each domain on the folding of the other. The same domain organization is shared by the related inositol 5-phosphatase INPP5B, which has a partially overlapping function with OCRL 9, 10 . However, INPP5B has not been associated with disease to date.
OCRL has a broad subcellular distribution. Although it was originally considered to be associated with the Golgi complex [11] [12] [13] , it also localizes to multiple stations of the endocytic pathway, such as latestage endocytic clathrin-coated pits and early endosomal sites [14] [15] [16] . This distribution is mediated by interactions with a variety of substrates, including the clathrin heavy chain (through two clathrin boxes in loops of the PH domain and the RhoGAP domain 14, 15 ), the clathrin adaptor AP-2 (through a motif adjacent to the PH domain 16 ), Rho family GTPases (through the RhoGAP domain 17 ) and Rab GTPases (through a site that, on the basis of mutagenesis studies, is thought to involve portions of the ASH domain 18, 19 ). In addition, the endocytic proteins APPL1 and Ses (both Ses1 and Ses2, referred to here as Ses1/2) are competitive interacting partners for the C terminus of OCRL 14, 20, 21 , binding to OCRL through a short peptide stretch (11-13 amino acids long) that contains an F&H motif 20 . Most of these interactions, with the exception of those involving clathrin, are shared by INPP5B, consistent with genetic evidence that OCRL and INPP5B have a partially overlapping function 10 .
In addition to the F&H motif, the APPL1 and Ses proteins also have a PH domain and an oligomerization surface 21 . APPL1, an adaptor protein that comprises a Bin-amphiphysin-Rvs (BAR) domain, a PH domain and a phosphotyrosine-binding (PTB) domain (Fig. 1a) , is present on a subpopulation of peripheral PtdIns(3)P-negative early endosomes 22, 23 . Conversely, Ses1/2, which contains a PH domain, a predicted coiled-coil and an extended unfolded region (Fig. 1a) , is localized on distinct intracellular vesicles including PtdIns(3)P-positive classical early endosomes 20 . As endosomes mature, the higher-affinity (for OCRL) Ses proteins displace APPL1 (ref. 20) , whereas OCRL remains associated with endocytic vesicles at both the APPL1 and Ses stage. The precise binding site for the F&H motif peptide in the ASH-RhoGAP domain of OCRL has not previously been mapped. However, it has been shown that F&H peptide binding requires the entire ASH-RhoGAP module 14, 20 .
The multiple localizations and interactions of OCRL are thought to help to coordinate intracellular membrane traffic with changes in a r t i c l e s the phosphoinositide composition of associated membranes. Equally, OCRL may prevent ectopic or excessive accumulation of PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 on intracellular membranes. Current models propose that a main function of OCRL is to regulate, through its action on membrane phosphoinositides, some aspect of endocytic and recycling membrane traffic. Such an action would explain the reabsorption defects in kidney proximal tubules that are characteristic of Lowe syndrome and Dent disease. Given the key role of phosphoinositides in the regulation of several membrane proteins and of interactions between membranes and cytoplasmic proteins, spatial control of OCRL recruitment may be as important as its intrinsic catalytic activity. Hence, a precise understanding of OCRL interactions is crucial for the elucidation of mechanisms of disease.
Although most disease-causing mutations in OCRL result in lack of protein expression, major truncations and deletions, or missense mutations which directly impair catalytic activity, there are also a group of missense mutations in the ASH-RhoGAP domain 3, 20, [24] [25] [26] [27] [28] [29] [30] . Cells derived from affected individuals carrying these mutations possess reduced 5-phosphatase activity [31] [32] [33] , a criteria for diagnosis, suggesting that mutations in the ASH-RhoGAP domain negatively affect some aspect of OCRL activity. Many of these missense mutations abolish interactions with proteins that contain F&H motifs, whereas some other interactions (such as that with clathrin) are preserved 14, 20, 27 . When it is overexpressed, OCRL protein bearing these mutations has a primarily diffuse, cytosolic localization 20, 27 .
To elucidate the structural basis of the interaction between the ASH-RhoGAP domain and the F&H motif, we have solved the crystal structure of the ASH-RhoGAP domain of OCRL in complex with a 13-amino-acid peptide from human Ses1 that includes the F&H motif. The peptide has a predominantly helical conformation and binds to a well-conserved groove on the posterior surface of the RhoGAP domain. These results explain the importance of protein folding in the generation of this binding surface and provide a framework to explain the effect of disease-causing mutations on ASH-RhoGAP domain interactions.
RESULTS
The ASH-RhoGAP domain in complex with the Ses1 F&H peptide To understand the molecular details of the interaction between the ASH-RhoGAP domain of OCRL and the F&H motif, we solved the crystal structure of the OCRL ASH-RhoGAP in complex with the minimal OCRL binding peptide from Ses1 (residues 223-235; Fig. 1a ,b and Table 1 ). As expected, the structure of the ASH-RhoGAP domain was very similar to that solved previously 14 , with differences in conformation primarily due to crystal packing interactions ( Supplementary Fig. 1a,b) . In this crystal form, the electron density for the entire ASH domain was visible due to contacts with neighboring molecules in the lattice. This allowed improved definition of this domain, which is structurally most similar to the major sperm protein (MSP) domain family as judged by a Dali search 34 (Supplementary Fig. 2 ). This prompted us to rename the ASH domain secondary structure elements according to the nomenclature previously adopted for VAP-A, a member of the MSP family 35 . Although several MSP proteins oligomerize, the ASH domain of OCRL a r t i c l e s is not involved in oligomer formation, as the ASH-RhoGAP domain of OCRL is monomeric in solution ( Supplementary Fig. 3 ).
The fold of the RhoGAP domain in the new crystal structure was almost identical to that of the previous structure, with an r.m.s. deviation of 0.47 Å. However, owing to crystal packing, there was no density for the long, clathrin box-containing loop observed in the previous structure. The ASH and RhoGAP domains were intimately connected to each other by a single α-helix of the ASH domain that was arranged as a hinge between the two domains. The orientation of the ASH domain relative to the RhoGAP domain differed slightly between the two structures as a result of a paddle-like motion centered on this hinge (Supplementary Fig. 1a) .
The F&H peptide from Ses1 had clear electron density and adopted a helical conformation, as would be expected from its heptad character (Fig. 1a,b) . It is bound to the RhoGAP domain at a surface opposite to its interface with the ASH domain. To our knowledge, no other structurally characterized RhoGAP uses this surface for protein-protein interactions.
Interactions between the RhoGAP domain and the F&H peptide
The interface between the F&H motif and the RhoGAP domain of OCRL is shown in detail in Figure 1b . The F&H helix docks against the back of the RhoGAP domain in the groove between helices αA and αE, and the residues that recognize the F&H proteins are highly specific for the RhoGAP domains of OCRL and INPP5B ( Supplementary  Fig. 4) . The nominative phenylalanine is tucked into a hydrophobic pocket formed by Phe842 and Phe746 of OCRL, where the side chain of Phe746 has rotated to accommodate this interaction. There are additional hydrophobic contacts mediated by residues Val734, Tyr838 and Leu839 in OCRL and Phe2, Leu5 and Tyr9 in the Ses1 peptide. The importance of Leu5 is consistent with the evolutionary conservation of a hydrophobic residue at this position 20 . The histidine side chain of the peptide forms a hydrogen bond with Asp743 of OCRL, and the main chain carbonyl of this residue forms a hydrogen bond with the indole nitrogen of Trp739.
The helical nature of the peptide is broken at position 11. This residue corresponds to the terminal proline in the minimal (11-mer) APPL1 F&H peptide (Fig. 1c) , which is otherwise predicted to have a similar α-helical fold. Thus, the helical portion of the F&H motif is equivalent in both the APPL1 and Ses1/2 adaptor families. The remainder of the Ses1 peptide loops back around with Glu12 establishing a hydrogen bond with Lys691, a residue at the base of the clathrin-binding loop, and Ile13 making further hydrophobic contacts with OCRL. The extra contacts mediated by these residues, which are present in both Ses1/2 but not APPL1, probably account for the higher binding affinity of Ses1/2 for OCRL than for APPL1 ( Table 2) .
In APPL1, a serine is required in position 1 of the peptide (a proline in Ses1). Thus, although the core helical F&H binding mode is likely to be the same for the two proteins, there are small differences between the Ses peptides and the APPL1 peptide in regard to the contributions of the N-and C-terminal residues. Accordingly, mutation of the first proline in the Ses1 peptide to serine increases the affinity of the peptide to one similar to the higher-affinity Ses2 peptide. The Ses2 F&H peptide has a cysteine rather than a proline at this position, perhaps explaining the increase in affinity (Table 2 and Fig. 1c) . Attempts to co-crystallize the ASH-RhoGAP domain in complex with the APPL1 peptide were unsuccessful.
Phosphorylation of Ser410 in APPL1 by PKA abolishes its interaction with OCRL 14 . In addition, the first serine residue in the APPL1 F&H motif has been reported as a phosphorylation site 36 . Surface plasmon resonance (SPR) showed that phosphorylated serines at either position in the APPL1 peptide severely interfered with the interaction of GST-tagged ASH-RhoGAP constructs ( Table 2 ). The mechanism of this effect on binding is not clear from the structure, but it may involve either destabilization of the helical conformation of the peptide or charge repulsion from neighboring residues. The negative effect of the phosphorylation of the serine residue at the first position confirms the importance of this residue for APPL1 binding.
Mutational analysis of the F&H binding site
To validate the F&H binding surface in the ASH-RhoGAP domain, we engineered mutations in this domain that were expected to affect binding and tested them in biochemical assays and living cells. We mutated Trp739 to alanine to perturb the hydrophobic surface without affecting the stability of the protein (Fig. 1b) . We also mutated Asp743 to the large, positively charged arginine. Both mutations disrupted binding of APPL1,which contains an F&H motif, but not of clathrin in glutathione S-transferase (GST) pulldowns from a rat brain extract using GST fusions of wild-type and mutant ASH-RhoGAP constructs as bait (Fig. 1d) .
We tested the OCRL W739A mutation in a variety of assays. GST pulldowns from COS-7 cells using fusions of APPL1 and Ses1 F&H peptides as bait showed binding of endogenous and transfected GFPtagged wild-type OCRL (OCRL WT ), but not of GFP-OCRL W739A (Supplementary Fig. 5 ). Likewise, SPR experiments revealed binding of purified recombinant ASH-RhoGAP WT , but not ASHRhoGAP W739A , to F&H peptides from APPL1 and Ses1/2 ( Table 2 and Supplementary Fig. 6 ).
To determine whether disruption of the F&H peptide interface on OCRL affected the colocalization of OCRL with APPL1 and Ses, we expressed GFP-OCRL WT and GFP-OCRL W739A in fibroblasts derived from individuals with Lowe syndrome 37 . The use of these cells allowed us to avoid potential artifacts due to competition with the endogenous enzyme. Both GFP-OCRL WT and GFP-OCRL W739A had broad and similar distributions in vesicular structures throughout cells, with an additional concentration in the Golgi complex area that was variable from cell to cell (Fig. 2) . Furthermore, as described for wild-type cells 20, 22 , APPL1 localized to a peripheral subpopulation of endosomes, whereas Ses2 was localized on more centrally located organelles, primarily endosomes and vesicles in the Golgi complex area, in cells expressing GFP-OCRL WT . GFP-OCRL WT colocalized with both APPL1 and Ses2 on these two populations of vesicles, whereas GFP-OCRL W739A showed a substantial reduction in colocalization with either protein (78% reduction for APPL1 and 60% for Ses2; P < 0.0001). The overall localization of APPL1 on peripheral vesicles seemed to be similar in cells expressing GFP-OCRL WT and in those expressing GFP-OCRL W739A (or even in the total absence of OCRL 14, 27 ), probably owing to the direct binding of APPL1 to Figure 1c . Owing to the slow loss of GST-fusion proteins, the K d estimates were higher in SPR than in the previous ITC studies 14, 20 by a factor of approximately 4, but the trends in affinities remained consistent. NB, no binding was detected.
Representative traces can be found in the Supplementary Figure 6 .
a r t i c l e s the early endosomal Rab5 (refs. 23, 27, 38) . By contrast, Ses2 was largely cytosolic when expressed in the absence of OCRL or when coexpressed with OCRL W739A , which indicates that its localization depends on OCRL. These studies verify that the crystallographically identified F&H motif recognition surface is required for the colocalization of OCRL with F&H proteins on endosomal compartments. It will be interesting to determine whether OCRL W739A can rescue defects observed in cells that lack OCRL. Such an analysis will require robust quantitative assays that so far have not been developed.
Conservation in the F&H binding site
Strong support for the physiological importance of the F&H binding site on the ASH-RhoGAP domain of OCRL comes from the high conservation of this site throughout evolution. When we used the amino acid sequences of 46 OCRL or INPP5B homologs to map the conservation of residues onto the surface of the ASH-RhoGAP structure, the F&H binding surface was one of two highly conserved sites (Fig. 3) . This conservation was specific for the RhoGAP domain of OCRL or INPP5B proteins (Supplementary Fig. 4 ). This interface is conserved in diverse lower organisms, such as trypanosomes, that encode an OCRL or INPP5B homolog (Fig. 3) but neither APPL1 nor Ses1/2. This leads us to speculate that other F&H proteins that function with OCRL might have been conserved during evolution. Unexpectedly, the OCRL or INPP5B homolog in Caenorhabditis elegans (NP_001122420) does not contain the appropriate residues for interaction with proteins that contain F&H motifs. This interaction may be lost, or the F&H motif binding site may have diverged or coevolved with an F&H motif-containing protein.
Another highly conserved surface mapped onto the ASH domain (Fig. 3) . As mutations in this region affect Rab5 binding (ref. 19 and below), this surface probably represents the Rab binding site.
Effect of disease-associated mutations on the ASH-RhoGAP domain
Most missense mutations in the ASH-RhoGAP domain that are found in individuals with Lowe syndrome result in loss of binding to APPL1 or Ses1/2 (refs. 14, 20, 27) . However, none of these mutations map to the F&H binding site. As the bound F&H peptide is wedged between two helices on the OCRL RhoGAP domain, it follows that the interaction requires a folded domain.
Given the extensive contact between the two domains 14 , it is clear that the stability of the ASH and RhoGAP domains are intertwined: destabilizing one will probably affect the stability of the other. In addition, binding partners may help to stabilize the conformation of the ASH-RhoGAP pair. For example, the tip of the ASH domain, which probably includes residues that are important for Rab binding (ref. 19 and below), is unstructured in the previous crystal structure but is stabilized here by crystal packing interactions ( Supplementary  Fig. 1b) . This difference could explain previous work showing that some mutants in which F&H binding is defective can recognize Rac1 or Rab5 (refs. 14,27). The folded G protein partners may be able to compensate for the destabilization of the ASH-RhoGAP domain, whereas the short F&H motif cannot.
As the crystal structure reported here comprises the fully ordered ASH-RhoGAP unit, it provides us with the opportunity to map precisely the locations of all of the currently described missense mutations a r t i c l e s found in the ASH-RhoGAP domain, expanding on the number of mutations previously analyzed (∆E585, A797P and I768N) 14 .
A common theme that emerges is the convergence of mutations from affected individuals onto specific regions of both the ASH and RhoGAP domains, pointing toward networks of amino acids that probably have key importance in maintaining stability. In the ASH domain, deletion of Glu585 (∆E585) alters affinity for both Rab5 and APPL1 (refs. 14,20,27) . This mutation disrupts the alternating hydrophobic-hydrophilic register of a β-sheet in the ASH domain and probably causes a global folding defect in the protein 14 . Another mutation that impairs F&H binding, L634P, occurs at a residue adjacent to Glu585 on a neighboring strand. The V577E mutation maps to the hydrophobic core of the ASH domain, and mutation of valine to a charged amino acid would directly impinge on the stability of the two β-strands that bear Glu585 and Leu634 (Fig. 4) .
All ASH domains contain an asparagine residue that is absolutely conserved 39 (Supplementary Fig. 2 ). The N591K mutation, which causes Lowe syndrome, corresponds to this residue. Structurally, the side chain of this residue is important for conferring the conformation of the tip of the ASH domain by forming multiple hydrogen bonds with residues in this region (Supplementary Fig. 7 ).
In the RhoGAP domain, Ile768 (I768N) stabilizes interactions between helices αA1 and αB, and that position is frequently occupied by a residue with a small, hydrophobic side chain in related RhoGAPs 14 (Supplementary Fig. 3 ). In addition, Leu891 (L891R; ref. 28) in the αG helix is involved in hydrophobic packing, and changing this residue to one with a hydrophilic side chain would disrupt folding. Mutations A797P 14 , P799L and P801L would all be detrimental to the proper folding of a region that contains the end of helix αB (A797P) and the following loop (P799L, P801L), in which the proline residues impose a unique conformation. Helix αB contains components that are involved in recognizing Rho GTPases in related GAPs 40 . In addition, these mutations cluster in the vicinity of residues 687 (L687P), 679 (C679W) and 737 (E737D) 30 , which contact each other in the interior of the folded protein. This cluster includes a residue at the base of helix αA (Glu737). This helix contains residues that recognize the F&H motif directly, relating this amino acid network to the formation of the F&H binding site.
Consistent with a predicted defect in folding, recombinant ASH-RhoGAP constructs bearing disease-causing mutations that disrupt F&H motif binding show markedly enhanced degradation and co-purify with a greater amount of bacterial chaperone protein than the wild-type construct (Fig. 4) . By contrast, ASH-RhoGAP domains harboring disease-causing mutations that do not abolish F&H motif recognition-F668V and A861T 20 -did not show conformational destabilization when prepared under identical conditions (Fig. 4) . A recent analysis of fibroblasts from affected individuals bearing the P801L and P799L mutations (causing Lowe syndrome and Dent disease, respectively) showed decreased protein content when compared to wild-type control cell lines 28 . In addition, a study of the interactions of the Ses proteins with OCRL also recently demonstrated destabilization of the full-length enzyme by missense mutations in the ASHRhoGAP domain 21 .
The A861T mutation is a splice site mutation, which leads to a lack of protein product 28 . Phe668 is incorporated into a site of very high conservation in the ASH domain (Fig. 3a) that also comprises residues that affect Rab interactions 19 , suggesting that its mutation to a much smaller side chain might impair Rab binding. We tested this hypothesis Inspection of a Coomassie blue-stained gel shows significant degradation as well as the co-purification of a DnaK chaperone for mutants that show a lack of F&H binding. This destabilization is not seen in our designed F&H-binding mutation (W739A), a Rab5-defective mutant (F668V) or a splice-site mutation that results in a lack of expressed protein (A861T). Asterisks, mutations that cause Dent 2 disease. Molecular weights of markers are indicated in kDa. (c) The GST-ASH-RhoGAP OCRL constructs in b were assessed for APPL1 binding using a GST pulldown assay from rat brain followed by western blot for APPL1. Figure 5 Characterization of a mutation that impairs binding of Rab5.
(a) Residues shown to be important for Rab binding both in previous studies 19 and here (Phe668), are represented by gray spheres. (b) Pulldowns using nucleotide-loaded Rab5 as bait for overexpressed OCRL constructs show that the GTPγS-dependent interaction between Rab5 and OCRL is perturbed by the F668V mutation, but not affected by mutation of the F&H recognition site. VOLUME 18 NUMBER 7 JULY 2011 nature structural & molecular biology a r t i c l e s using a standard Rab5 GST pulldown assay and confirmed that this mutant was defective in interactions with Rab5 (Fig. 5) . The crystal structure of the complex of a Rab (Rab8) with the OCRL ASH domain was published while this manuscript was under revision 41 . The interaction surface we predicted in this study, and the importance of Phe668 for Rab recognition, is consistent between the two studies.
Given the high conservation of the F&H binding surface, it is surprising that so far no disease-causing mutation has mapped directly to this site. These mutations may exist and may be found in the future. Alternatively, direct mutations of the F&H binding site may not be compatible with life.
DISCUSSION
The structure of the OCRL ASH-RhoGAP domain in complex with a peptide from Ses1 shows how the ASH-RhoGAP domain recognizes the F&H consensus motif and explains the tolerance for differences between the APPL1 and Ses1/2 sequences. The F&H recognition site on OCRL verifies the importance of protein folding in its formation 14 and shows why mutations that are spread throughout the ASHRhoGAP domain can abolish F&H binding. Furthermore, we show that these mutations impair protein stability. This is in agreement with recent studies of OCRL protein content in fibroblasts derived from individuals affected with each disorder 28 , which found that OCRL bearing missense mutations in the ASH-RhoGAP domain is not expressed at normal levels, despite the presence of normal amounts of OCRL mRNA.
Our findings support the idea that interactions of the ASH-RhoGAP domain have a key role in the physiological function of OCRL, probably by defining the membrane and membrane subdomains in which OCRL must exercise its 5-phosphatase function. This is supported by imaging studies of OCRL proteins bearing some of these disease-causing mutations 14, 27 . As at least one disease-causing mutation, F668V, impairs Rab binding but preserves F&H motif binding, it seems that the two interactions cannot compensate for each other, in spite of the fact that they partially cooperate in localizing OCRL to endosomes 27 .
The F&H binding site is highly conserved throughout evolution in all organisms that express OCRL or INPP5B proteins, in spite of the absence of APPL1 and Ses in some of these organisms. The identification of unknown interactors with this site is likely to reveal new fundamental aspects of the function of OCRL, with potential relevance for the elucidation of disease mechanisms in Lowe syndrome and Dent disease.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
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